This grant will support further scientific development of NOV-002, in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track.
Christopher Pazoles, vice president of R&D, said: “This small business technology transfer program (STTR) award enables Novelos to accelerate and broaden the scope of investigation around NOV-002’s mechanism of action in relation to its unique therapeutic profile. This grant process is very competitive, and NIH’s choice of Novelos to move this important work forward signals confidence in our technology platform and our expertise.”
Principal investigator of the grant, Kenneth Tew, said: “NOV-002 is a novel drug capable of modifying redox-based cell processes and represents a valuable tool for linking such processes to clinical endpoints in oncology patients. The research supported by this initial STTR grant will focus on continued identification of the molecular targets of NOV-002 and the therapy-relevant consequences of their modulation.”